Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,788.80
(
0.70%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
105.04
(
0.82%
)
Bitcoin
80,492.00
(
-0.70%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 163702

Wednesday, 07/17/2013 11:12:28 AM

Wednesday, July 17, 2013 11:12:28 AM

Post# of 257566
(ENTA)—NVS’ 2Q13 PR* (p24) says the partial clinical hold on DEB025 has been “revised” and a DDI study has been started. The revision was presumably the FDA’s permission to conduct the DDI study, and I’m guessing that the second drug in the DDI study is ENTA’s EDP-239. (ENTA is +3% today.)

*http://www.novartis.com/cs/www.novartis.com-v4/downloads/investors/financial-results/quarterly-results/2013-07-interim-financial-report-en.pdf

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today